ライフサイエンスコーパス: recurrent ovarian cancer

1 definitive treatment for platinum-sensitive recurrent ovarian cancer.

2 therefore frequent in chemotherapy resistant recurrent ovarian cancer.

3 survival in patients with platinum-sensitive recurrent ovarian cancer.

4 atment for patients with platinum-sensitive, recurrent ovarian cancer.

5 vide women with a new therapeutic option for recurrent ovarian cancer.

6 ndard treatment option for platinum-eligible recurrent ovarian cancer.

7 modality in the treatment of metastatic and recurrent ovarian cancer.

8 ibitor that has shown antitumour activity in recurrent ovarian cancer.

9 ation has a limited role in the detection of recurrent ovarian cancer.

10 CT may have similar accuracy in detection of recurrent ovarian cancer.

11 l as prognostic biomarkers for patients with recurrent ovarian cancer.

12 le tolerance in the second-line treatment of recurrent ovarian cancer.

13 tin-refractory cancer cells in patients with recurrent ovarian cancer.

14 iologic activity and safety of etanercept in recurrent ovarian cancer.

15 a novel treatment for chemotherapy-resistant/recurrent ovarian cancer.

16 y, and therapeutic efficacy of etanercept in recurrent ovarian cancer.

17 CT-2103 is active in patients with recurrent ovarian cancer.

18 sequent response to platinum chemotherapy in recurrent ovarian cancer.

19 t prolongation of survival for patients with recurrent ovarian cancer.

20 V ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer.

21 n the maintenance treatment of patients with recurrent ovarian cancer.

22 erapy and laparotomy-confirmed persistent or recurrent ovarian cancer.

23 weekly as a 1-hour infusion in patients with recurrent ovarian cancer.

24 m management interventions for patients with recurrent ovarian cancer.

25 onses (>12 months) in 25.0% of patients with recurrent ovarian cancer.

26 initial diagnosis, and more frequently with recurrent ovarian cancer.

27 ay represent a future treatment strategy for recurrent ovarian cancer.

28 cytoreductive surgery for platinum-sensitive recurrent ovarian cancer.

29 de serous or endometrioid platinum-sensitive recurrent ovarian cancer.

30 n (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, pl

31 ted activity in patients with progressive or recurrent ovarian cancer after first-line platinum-based

32 Patients with recurrent ovarian cancer after one or two prior chemothe

33 rogression-free survival among patients with recurrent ovarian cancer after platinum-based chemothera

34 Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were elig

35 any agents are approved for the treatment of recurrent ovarian cancer, and the treatment of each pati

36 gents have antitumour activity in women with recurrent ovarian cancer, and their combination was acti

37 of this regimen in women with refractory or recurrent ovarian cancer are necessary before it can be

38 Treatment options for recurrent ovarian cancer are of limited clinical benefit

39 undation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity.

40 Topotecan is known to be active in recurrent ovarian cancer, but most prior studies have fo

41 In this era of advanced medical technology, recurrent ovarian cancer continues to be a therapeutic d

42 and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve P

43 al chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive

44 regimens were administered to 176 women with recurrent ovarian cancer during this time period, with a

45 atients with BRCA-mutated platinum-sensitive recurrent ovarian cancer following response to chemother

46 erapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repai

47 ificantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum.

48 Recurrent ovarian cancer is also an important setting in

49 eatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during the diseas

50 linical value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency

51 erapy plus bevacizumab in platinum-sensitive recurrent ovarian cancer is planned.

52 Eligible patients had recurrent ovarian cancer, measurable disease per immune-

53 y for suspected new ovarian cancer (n = 26), recurrent ovarian cancer (n = 5), or endometrial cancer

54 s activity and tolerability in patients with recurrent ovarian cancer (OC) or primary peritoneal carc

55 in monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation a

56 Immunotherapy has shown limited success in recurrent ovarian cancer (OC), with prognostic insights

57 expansion cohorts of patients with advanced, recurrent ovarian cancer or malignant mesothelioma recei

58 The majority of women with recurrent ovarian cancer (OvCa) develop malignant ascite

59 rous malignant ascites from highly resistant recurrent ovarian cancer patients were isolated and ampl

60 Recurrent ovarian cancer patients, especially those resi

61 l activity in a cohort of heavily pretreated recurrent ovarian cancer patients.

62 7-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients.

63 d activity are decreased in chemotherapeutic recurrent ovarian cancer patients.

64 The trial accrued 40 heavily pretreated recurrent ovarian cancer patients.

65 Treatments for advanced and recurrent ovarian cancer remain a challenge due to a lac

66 ctive therapy against chemotherapy-resistant/recurrent ovarian cancer remains a high priority.

67 State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-

68 Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progres

69 utics for treating women with late-stage and recurrent ovarian cancers, utilizing a mechanism distinc

70 oved agents in women with platinum-sensitive recurrent ovarian cancer warrants further evaluation.

71 One patient with recurrent ovarian cancer who received 16 courses of ther

72 s to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase

73 Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutat